Aventis Merger Would Require Revasc Divestiture; Novartis Has First Rights
Executive Summary
Rhone-Poulenc Rorer would divest its direct thrombin inhibitor candidate Revasc (desirudin) in order to complete its merger with Hoechst Marion Roussel into Aventis, a Dec. 7 consent order provisionally accepted by the Federal Trade Commission states.
You may also be interested in...
Specialty Pharma Canyon Takes Leech-Inspired Anticoagulant Approved In 2003 To Market
Iprivask, "the first direct thrombin inhibitor approved in the U.S.," was found superior to both heparin and Lovenox but fell through the cracks during pharma M&A activity, Canyon exec says.
Aventis Retains Revasc; Refludan Divestment Ordered By FTC
Aventis' Refludan is available for licensing through the New York City investment banking company Ferghana Partners as a result of an Aug. 25 Federal Trade Commission order.
Aventis Retains Revasc; Refludan Divestment Ordered By FTC
Aventis' Refludan is available for licensing through the New York City investment banking company Ferghana Partners as a result of an Aug. 25 Federal Trade Commission order.